Novo Nordisk outlined an ambitious plan to launch more than five multi-blockbuster drugs and target pipeline sales of over 150 billion Danish kroner ($23 billion) by 2035, supported by a broad mix of Phase III programs in obesity, diabetes, and other areas.

The company’s 2030 Capital Markets Day detailed a strategy to restore growth through expansion and diversification of the metabolic drug pipeline, aiming for five or more multi-blockbuster drugs annually through 2030 from over five Phase III obesity/diabetes programs and additional Phase III programs in other therapeutic areas.

Stock reactions were negative at first, with shares sliding up to about 7.7% after the Capital Markets Day reveal.

Investors noted a solid balance sheet and ongoing buyback activity, but near-term hurdles and pricing/patent concerns remain a focal point.

While the cadence of revenue growth from 2026 to 2030 was framed as peer-aligned, some analysts view the targets as potentially leaving downside risk and execution challenges.

A disappointing Phase 3 result for the experimental CagriSema lunged ahead of expectations, as it achieved 23% weight loss versus 25.5% for a competitor and failed to meet the primary endpoint of non-inferiority.

Investors viewed potential pricing pressure and future dealmaking as risks ahead of Wegovy and Ozempic patent expiries, contributing to a stock pullback.

The London Capital Markets Day signaled a strategic pivot to sustain growth amid a crowded market and patent risk.

Executives acknowledged patent expiry and pricing pressures, stressing diversification beyond semaglutide as a key resilience strategy.

Competitive pressure from Eli Lilly’s GLP-1 portfolio remains a headwind, with Lilly holding a larger share in obesity and weight-management therapies.

In the second quarter, NovoNordisk held about 39% of the obesity drug market versus Lilly’s roughly 61%, underscoring competitive dynamics.

The company disclosed a cost-cutting drive with about 13,000 total departures, reflecting an ongoing restructuring of expense structure.